Sign In
Buy HAE
$65.88
-0.490 (-0.738%)
At Close: Jun 03, 2026
Here's Why Haemonetics (HAE) is a Strong Value Stock
10:41am, Friday, 24'th Jan 2025
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
HAE or ABT: Which Is the Better Value Stock Right Now?
12:40pm, Monday, 20'th Jan 2025
Investors interested in Medical - Products stocks are likely familiar with Haemonetics (HAE) and Abbott (ABT). But which of these two companies is the best option for those looking for undervalued sto
Completion of Whole Blood Assets Sale to GVS Likely to Boost HAE Stock
09:06am, Monday, 20'th Jan 2025
Haemonetics completes the sale of whole blood assets to GVS, S.p.A.
Haemonetics Completes Sale of Whole Blood Assets to GVS, S.p.A
06:13am, Tuesday, 14'th Jan 2025
BOSTON , Jan. 14, 2025 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE), a global medical technology company focused on delivering innovative medical solutions to drive better patient outcomes, t
Haemonetics Sets Date for Publishing Third Quarter Fiscal Year 2025 Results: February 6, 2025
05:03pm, Wednesday, 08'th Jan 2025
BOSTON , Jan. 8, 2025 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) announced that the Company intends to publish third quarter fiscal year 2025 financial results at 6:00 am ET on Thursday, Febr
Why Haemonetics (HAE) is a Top Value Stock for the Long-Term
10:41am, Wednesday, 08'th Jan 2025
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Haemonetics to Present at 43rd Annual J.P. Morgan Healthcare Conference
06:00am, Monday, 06'th Jan 2025
BOSTON , Jan. 6, 2025 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) announced that Chris Simon, President and CEO, will present at the 43rd Annual J.P. Morgan Healthcare Conference in San Franci
HAE vs. ABT: Which Stock Is the Better Value Option?
12:51pm, Friday, 03'rd Jan 2025
Investors interested in stocks from the Medical - Products sector have probably already heard of Haemonetics (HAE) and Abbott (ABT). But which of these two stocks offers value investors a better bang
5 Beaten-Down MedTech Stocks Set to Rebound in 2025
09:25am, Monday, 30'th Dec 2024
Investors may want to take a closer look at discounted stocks, such as MCK, HAE, ARAY, LIVN and PBH, in the present market landscape.
Here's Why You Should Add HAE Stock to Your Portfolio Now
08:46am, Tuesday, 24'th Dec 2024
Strong prospects for the Plasma franchise and favorable solvency bode well for Haemonetics.
Down -11.82% in 4 Weeks, Here's Why You Should You Buy the Dip in Haemonetics (HAE)
10:36am, Monday, 23'rd Dec 2024
The heavy selling pressure might have exhausted for Haemonetics (HAE) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts
KalVista: Potential First With Multiple Sebetralstat Regulatory Reviews In 2025
01:46pm, Wednesday, 18'th Dec 2024
NDA submission of sebetralstat was accepted for review by the FDA as an on-demand treatment option for HAE patients, with a PDUFA review date of June 17th of 2025. If sebetralstat is approved by the F
HAE or SYK: Which Is the Better Value Stock Right Now?
12:40pm, Wednesday, 18'th Dec 2024
Investors with an interest in Medical - Products stocks have likely encountered both Haemonetics (HAE) and Stryker (SYK). But which of these two companies is the best option for those looking for unde
CSL Receives Positive CHMP Opinion for Garadacimab in Hereditary Angioedema (HAE)
10:38am, Friday, 13'th Dec 2024
If approved, garadacimab will be the first and only once-monthly treatment inhibiting factor XIIa to prevent attacks in HAE patients – a community CSL has been serving for more than 40 years MARBURG
Are Investors Undervaluing Haemonetics (HAE) Right Now?
10:41am, Friday, 06'th Dec 2024
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest
